Commentary

Video

Supplements and Featured Publications

Navigating New Data in the Breast Cancer Treatment Paradigm
Volume1
Issue 1

Dr Bardia on Findings From DESTINY-Breast06 in HER2-Low Breast Cancer

Aditya Bardia, MD, MPH, FASCO, discusses QOL outcomes among patients with HER2-low and HER2-ultralow breast cancer from the DESTINY-Breast06 trial.

Aditya Bardia, MD, MPH, FASCO, professor, Department of Medicine, Division of Hematology/Oncology, director, Translational Research Integration, member, Signal Transduction and Therapeutics, UCLA Jonsson Comprehensive Cancer Center, discusses the quality of life (QOL) outcomes in the HER2-low and HER2-ultralow populations of patients with metastatic hormone receptor–positive breast cancer who were treated with fam-trastuzumab deruxtecan-nxki (Enhertu; T-DXd) in the phase 3 DESTINY-Breast06 trial (NCT04494425).

The DESTINY-Breast06 trial included patients with both HER2-low and HER2-ultralow metastatic breast cancer and assessed the effects of T-DXd on QOL and survival, Bardia begins. T-DXd was associated with less deterioration in QOL and health-related QOL compared with standard chemotherapy, a crucial consideration for patients with metastatic breast cancer who need both extended survival and maintained QOL, he reports. Given that in this trial T-DXd was given in the post-endocrine therapy setting, these findings are particularly valuable, according to Bardia. Improved disease control with T-DXd was correlated with better QOL, as disease progression often worsens QOL, he adds. Notably, T-DXd was associated with sustained health-related QOL in several domains, although some patients experienced more nausea with T-DXd than with physician’s choice of chemotherapy, such as capecitabine, underscoring the importance of managing adverse effects (AEs), Bardia notes.

This positive study demonstrated a median progression-free survival (PFS) of 13.2 months with T-DXd, alongside a trend toward improved overall survival, he reports. Unlike previous studies, DESTINY-Breast06 enrolled both HER2-low and HER2-ultralow subgroups, he expands. Even within the HER2-ultralow subgroup, T-DXd generated superior outcomes over standard chemotherapy, showcasing the efficacy of the antibody-drug conjugate across patients with varied levels of HER2 expression, Bardia states. These findings emphasize the clinical value of T-DXd in this setting, offering effective disease control, improved PFS, and, in some patients, better QOL, as well as underscoring the need for AEmanagement to optimize treatment tolerance, he concludes.

Related Videos
Shubham Pant, MD, MBBS
Brett L. Ecker, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Howard S. Hochster, MD, FACP,
John H. Strickler, MD
Brandon G. Smaglo, MD, FACP
Cedric Pobel, MD
Ruth M. O’Regan, MD
Michael R. Grunwald, MD, FACP
Peter Forsyth, MD